Something in the air: hyperoxic conditioning of the tumor microenvironment for enhanced immunotherapy
RD Leone, MR Horton, JD Powell - Cancer cell, 2015 - cell.com
RD Leone, MR Horton, JD Powell
Cancer cell, 2015•cell.comRecent clinical trials in cancer therapy have demonstrated unprecedented responses
through blockade of CTLA-4 and PD-1 immune checkpoint pathways. In a provocative
recent paper in Science Translational Medicine, Hatfield and colleagues demonstrate the
ability of supplemental oxygen to act as a novel immune checkpoint inhibitor by disrupting
the hypoxia-adenosine-A2aR pathway.
through blockade of CTLA-4 and PD-1 immune checkpoint pathways. In a provocative
recent paper in Science Translational Medicine, Hatfield and colleagues demonstrate the
ability of supplemental oxygen to act as a novel immune checkpoint inhibitor by disrupting
the hypoxia-adenosine-A2aR pathway.
Recent clinical trials in cancer therapy have demonstrated unprecedented responses through blockade of CTLA-4 and PD-1 immune checkpoint pathways. In a provocative recent paper in Science Translational Medicine, Hatfield and colleagues demonstrate the ability of supplemental oxygen to act as a novel immune checkpoint inhibitor by disrupting the hypoxia-adenosine-A2aR pathway.
cell.com
